Tempest Therapeutics (NASDAQ:TPST) Trading Up 8.8%

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s share price was up 8.8% during trading on Monday . The stock traded as high as $1.87 and last traded at $1.85. Approximately 817,063 shares changed hands during trading, a decline of 15% from the average daily volume of 958,676 shares. The stock had previously closed at $1.70.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TPST shares. Piper Sandler reissued an “overweight” rating and set a $8.00 price target on shares of Tempest Therapeutics in a research report on Friday, June 21st. HC Wainwright reissued a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a research report on Thursday, June 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Tempest Therapeutics has an average rating of “Buy” and an average target price of $20.75.

Tempest Therapeutics Stock Performance

The stock has a market capitalization of $38.55 million, a P/E ratio of -1.08 and a beta of -1.73. The stock has a 50 day moving average of $2.54 and a 200 day moving average of $3.32. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.13 and a current ratio of 3.13.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08. Equities analysts predict that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.

Insider Transactions at Tempest Therapeutics

In other Tempest Therapeutics news, CEO Stephen R. Brady purchased 35,000 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was bought at an average price of $2.11 per share, with a total value of $73,850.00. Following the completion of the purchase, the chief executive officer now owns 46,376 shares in the company, valued at approximately $97,853.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders acquired 47,172 shares of company stock valued at $100,001. 3.27% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC boosted its holdings in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 69.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,574 shares of the company’s stock after buying an additional 11,689 shares during the period. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.